Indiana University- Simon Cancer Center

Indianapolis, Indiana 46202-5289

3 studies enrolling now · 88 studies all time

What they study most

AL Amyloidosis, Acute Leukemia, Acute Lymphoid Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Adenocarcinoma of the Pancreas, Adult Solid Tumor, Advanced Gastrointestinal Cancer, Advanced Solid Tumor, Advanced Solid Tumors, Advanced or Metastatic (Medically or Surgically Unresectable) Clear-cell Renal Cell Carcinoma, Anemia, Refractory, With Excess of Blasts

Studies at this site

• BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) — Recruiting now
• A Study of Tetrathiomolybdate (TM) Plus Capecitabine — Recruiting now
• The Indiana Myeloma Registry — Recruiting now
• Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer — Running, not enrolling
• Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] — Completed
• MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC — Completed
• Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) — Running, not enrolling
• ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer — Completed
• Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma — Running, not enrolling
• Cisplatin vs Paclitaxel for Triple Negative Breast Cancer — Completed
• Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age — Completed
• Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination — Completed
• A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors — Running, not enrolling
• Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery — Completed
• Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer — Completed
• A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors — Completed
• Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies — Completed
• A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) — Running, not enrolling
• TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) — Completed
• Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant — Running, not enrolling
• A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies — Completed
• A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer — Completed
• A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors — Completed
• Role of Osteocytes in Myeloma Bone Disease — Completed
• A Safety Study of SGN-LIV1A in Breast Cancer Patients — Completed
• Selinexor Treatment of Refractory Myeloma — Completed
• Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) — Completed
• A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma — Stopped early
• A Phase II Study of Neoadjuvant FOLFIRINOX — Completed
• A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas — Completed
• Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer — Completed
• Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer — Completed
• Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) — Stopped early
• Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer — Stopped early
• Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma — Completed
• Selecting a Favorable KIR Donor in Unrelated HCT for AML — Completed
• Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer — Completed
• Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies — Stopped early
• Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer — Stopped early
• A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer — Completed
• Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer — Completed
• A Study of APX3330 in Patients With Advanced Solid Tumors — Completed
• Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer — Completed
• A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer — Stopped early
• Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer — Completed
• Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry — Completed
• Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC) — Completed
• Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas — Completed
• Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma — Stopped early
• Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma — Status unconfirmed